Fusion protein strategy to increase expression and solubility of hypervariable region of VP2 protein of infectious bursal disease virus in Escherichia coli
- PMID: 22865249
- DOI: 10.1007/s10930-012-9437-2
Fusion protein strategy to increase expression and solubility of hypervariable region of VP2 protein of infectious bursal disease virus in Escherichia coli
Abstract
Infectious bursal disease is one of the most important viral diseases in the young chickens. VP2 protein is the major host protective immunogen of the virus. A hypervariable region is present in VP2 protein (hvVP2) that contains immunodominant epitops. The high hydrophobicity of hvVP2 region causes protein aggregation in Escherichia coli (E. coli). The objective of the present study was to improve the expression and the solubility of the hvVP2 protein in E. coli. The effects of fusion partners on the solubility of hvVP2 protein were studied. The protein was expressed in forms of unfused and N-terminally fused to GST and NusA. The results showed that the unfused hvVP2 protein was expressed in very low level. But, N-terminally fused hvVP2 protein to GST (glutathione-S-transferase) and NusA (N utilization substance A) showed significantly enhanced protein expression. The fusion of GST and hvVP2 was produced in aggregated form while in the presence of NusA, the hvVP2 protein was expressed in a soluble form. The NusA-hvVP2 protein was detected by a neutralizing monoclonal antibody, 1A6, in antigen-capture ELISA. In conclusion, the NusA protein is a suitable fusion partner to improve expression and solubility of the hvVP2 protein in E. coli.
Similar articles
-
Soluble overexpression and purification of infectious bursal disease virus capsid protein VP2 in Escherichia coli and its nanometer structure observation.Cell Cycle. 2022 Jul;21(14):1532-1542. doi: 10.1080/15384101.2022.2056305. Epub 2022 Mar 28. Cell Cycle. 2022. PMID: 35343377 Free PMC article.
-
Infectious bursal disease subunit vaccination.Avian Dis. 2008 Dec;52(4):670-4. doi: 10.1637/8289-032008-ResNote.1. Avian Dis. 2008. PMID: 19166061 Clinical Trial.
-
High level soluble expression and one-step purification of IBDV VP2 protein in Escherichia coli.Biotechnol Lett. 2016 Jun;38(6):901-8. doi: 10.1007/s10529-016-2073-8. Epub 2016 Mar 22. Biotechnol Lett. 2016. PMID: 27003577
-
Soluble expression of archaeal proteins in Escherichia coli by using fusion-partners.Protein Expr Purif. 2008 Nov;62(1):116-9. doi: 10.1016/j.pep.2008.06.015. Epub 2008 Jul 10. Protein Expr Purif. 2008. PMID: 18657619
-
Enhanced soluble expression of recombinant Flavobacterium heparinum heparinase I in Escherichia coli by fusing it with various soluble partners.Protein Expr Purif. 2012 Jun;83(2):169-76. doi: 10.1016/j.pep.2012.03.016. Epub 2012 Apr 7. Protein Expr Purif. 2012. PMID: 22503820
Cited by
-
Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli.Virol Sin. 2013 Feb;28(1):43-8. doi: 10.1007/s12250-013-3286-9. Epub 2013 Jan 17. Virol Sin. 2013. PMID: 23329470 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials